The programmed cell death 1 ligand 1 (PD-L1) immunotherapy atezolizumab demonstrated a statistically significant disease-free survival (DFS) benefit compared with best supportive care (BSC) among patients with resected stage II-IIIA NSCLC who received adjuvant chemotherapy in the randomized, open-label, phase III IMpower010 clinical trial (NCT02486718) [10,11,13]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.